modelR03DX05
Extends from Pharmacokinetic.Models.PK_2C.
Information
| name: | Omalizumab | |
| ATC code: | R03DX05 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 150 | mg |
| volume of distribution: | 7.47 | L |
| clearance: | 2.4 | mL/min |
| other parameters in model implementation | ||
Omalizumab is a humanized monoclonal antibody that selectively binds to immunoglobulin E (IgE). It is primarily used as an add-on therapy for moderate to severe persistent allergic asthma not adequately controlled with inhaled corticosteroids. Omalizumab is also approved for treatment of chronic spontaneous urticaria. The drug is administered subcutaneously and is approved in the United States, Europe, and many other countries.
Pharmacokinetics
Population pharmacokinetics in adult and adolescent patients with moderate to severe allergic asthma after subcutaneous administration.
References
Luu, M, et al., & Goirand, F (2016). Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert opinion on drug metabolism & toxicology 12(12) 1503–1511. DOI:10.1080/17425255.2016.1248403 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27748630
Plosker, GL, & Keam, SJ (2008). Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 22(3) 189–204. DOI:10.2165/00063030-200822030-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18481901
Lowe, PJ, et al., & Jimenez, P (2009). Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. British journal of clinical pharmacology 68(1) 61–76. DOI:10.1111/j.1365-2125.2009.03401.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19660004
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)